VALERIE OWEN: Open Payments
NPI 1457809055 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,091 in 70 payments from 14 companies in 2025. Trend: 2023 $1,948 · 2024 $7,915 · 2025 $2,091
Food & beverage: $2,091
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 9 | $385 |
| Enterra Medical, Inc. | 2 | $340 |
| ABBVIE INC. | 20 | $290 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 10 | $205 |
| QOL Medical, LLC | 8 | $173 |
| Ardelyx, Inc. | 4 | $171 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $164 |
| Janssen Biotech, Inc. | 1 | $90 |
| Madrigal Pharmaceuticals | 1 | $74 |
| Regeneron Healthcare Solutions, Inc. | 3 | $68 |
Products named: DUPIXENT, XIFAXAN, Sucraid, IBSRELA, RINVOQ, SKYRIZI, TREMFYA, ENTYVIO.
Industry payments across MD — which companies pay providers there.
